MyChesCo on MSN1d
FDA Approves TREMFYA® for Crohn’s Disease, Offering New Treatment Options
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
Healio2d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Zacks Investment Research on MSN2d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease
Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
MPR2d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...
The American Journal of Managed Care2d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
pharmaphorum2d
J&J adds to IL-23 options in Crohn's after FDA approval
Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...
BioSpace2d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Managed Healthcare Executive2d
FDA Approves Tremyfa to Treat Active Crohn’s Disease
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
Fierce Pharma3d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease
Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor ...
Yahoo Finance2d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn's disease ...